Dyslipidemia Epidemiology Forecast 2025-2034

Depending on the definition and criteria used, the global prevalence of dyslipidemia in adults ranges from 20% to 80%, as per a systematic review. The World Health Organization (WHO) reports that 39% of adults worldwide have high blood cholesterol, with a slightly higher occurrence in women.

Dyslipidemia Epidemiology Forecast Report Coverage

The “Dyslipidemia Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Dyslipidemia. It projects the future incidence and prevalence rates of Dyslipidemia across various populations. The study covers age and type as major determinants of the Dyslipidemia-affected population. The report highlights patterns in the prevalence of Dyslipidemia over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of dyslipidemia in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Dyslipidemia: Disease Overview

Dyslipidemia is a condition characterized by abnormal levels of fats (lipids) in the blood. It is reported to significantly increase the risk of heart disease, stroke, and other cardiovascular issues. Dyslipidemia can be caused by poor diet, lack of exercise, obesity, genetic factors, and medical conditions like diabetes or hypothyroidism. The condition often goes unnoticed because it typically has no obvious symptoms. However, if left untreated, dyslipidemia can lead to the development of atherosclerosis and other serious cardiovascular problems.

Dyslipidemia: Treatment Overview

The treatment for dyslipidemia usually involves a combination of lifestyle changes and medications (whenever necessary). Statins, such as atorvastatin and simvastatin, are the most commonly prescribed drugs to lower LDL cholesterol and reduce the risk of cardiovascular disease. Fibrates, including gemfibrozil and fenofibrate, are primarily taken to lower triglycerides. PCSK9 inhibitors are recommended for patients with high cholesterol who don't respond to statins.

Epidemiology

The dyslipidemia epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for dyslipidemia by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for dyslipidemia and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• About 39% of adults worldwide have high blood cholesterol, with a slightly higher prevalence in women (40%) than in men (37%), as per the World Health Organization (WHO).
• A systematic review estimates that the global prevalence of dyslipidemia in adults ranges from 20% to 80%, depending on the definition and criteria used.
• A US study found that 7% of children and adolescents between the ages of 6 and 19 had elevated total cholesterol. It was also reported that 22% had at least one abnormal lipid level.

Gender Based Dyslipidemia Insights

A real-world study published in Lipids in Health and Disease (2023) estimated the overall prevalence of dyslipidemia to be 13.17%, with a significantly higher rate in men (23%) compared to women (7.2%). The physiological differences in fat distribution affect the prevalence of dyslipidemia in males and females. Males tend to store more visceral fat (around internal organs), while women store subcutaneous fat (under the skin). As a result, the lipid levels vary.

Country-wise Dyslipidemia Epidemiology

The dyslipidemia epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of dyslipidemia varies significantly between countries due to differences in genetic predispositions, lifestyle patterns, socioeconomic status, healthcare infrastructure, and the prevalence of risk factors, such as diet, physical activity levels, and obesity rates, among others. As per the Indian Council of Medical Research-India Diabetes (ICMR-INDIAB) study, significant regional variations in hypercholesterolemia (cholesterol levels =200 mg/dl) were found in India, with prevalence ranging from 4.6% to 50.3%.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of dyslipidemia based on several factors.
• The Dyslipidemia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of dyslipidemia are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of dyslipidemia epidemiology in the 8 major markets?
• What will be the total number of patients with dyslipidemia across the 8 major markets during the forecast period?
• What was the country-wise prevalence of dyslipidemia in the 8 major markets in the historical period?
• Which country will have the highest number of dyslipidemia patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of dyslipidemia during the forecast period of 2025-2034?
• What are the currently available treatments for dyslipidemia?
• What are the disease risks, signs, symptoms, and unmet needs of dyslipidemia?

This product will be delivered within 3-5 business days.